Risks of clinically significant upper gastrointestinal events with etodolac and naproxen: A historical cohort analysis

Gastroenterology

Volumn 127, Issue 5, 2004, Pages 1322-1328

  Weideman, Rick A ^a   Kelly, Kevin C ^a   Kazi, Salahuddin ^a,b   Cung, Anh ^a   Roberts, Kevin W ^a   Smith, Herbert J ^a   Sarosi Jr , George A ^a,b   Little, Bertis B ^a,c   Cryer, Byron ^a,b  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c TARLETON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; ETODOLAC; NAPROXEN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SAFETY; DUODENUM PERFORATION; DUODENUM ULCER; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; STOMACH OBSTRUCTION; STOMACH PERFORATION; STOMACH ULCER;

EID: 7644232150     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2004.08.016     Document Type: Article

References (15)

1. M.M. Wolfe, D.R. Lichtenstein, G. Singh Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs N Engl J Med 340 1999 1888 1899
2. F.E. Silverstein, G. Faich, J.L. Goldstein, L.S. Simon, T. Pincus, A. Whelton, R. Makuch, G. Eisen, N.M. Agrawal, W.F. Stenson, A.M. Burr, W.W. Zhao, J.D. Kent, J.B. Lefkowith, K.M. Verburg, G.S. Geis Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis JAMA 284 2000 1247 1255
3. C. Bombardier, L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, B. Davis, R. Day, Bosi-Ferraz, C.J. Hawkey, M. Hochberg, T.K. Kvien, T.J. Schnitzer VIGOR Study Group Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis N Engl J Med 343 2000 1520 1528
4. T.D. Warner, F. Giuliano, I. Vojnovic, A. Bukasa, J.A. Mitchell, J.R. Vane Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity a full in vitro analysis Proc Natl Acad Sci U S A 96 1999 7563 7568
5. L. Laine, R. Sloane, M. Ferretti, F. Cominelli A randomized, double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production Gastrointest Endosc 42 1995 428 433
6. M. Langman, D. Jensen, D. Watson, S.E. Harper, P.L. Zhao, H. Quan, J.A. Bolognese, T.J. Simon Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs JAMA 282 1999 1929 1933
7. J.L. Goldstein, F.E. Silverstein, N.M. Agrawal, R.C. Hubbard, J. Kaiser, C.J. Maurath, K.N. Verburg, G.S. Geis Reduced risk of upper gastrointestinal ulcers with celecoxib, a COX-2 inhibitor Am J Gastroenterol 95 2000 1681 1690
8. L. Laine Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient Gastroenterology 120 2001 594 606
9. W.A. Ray, C.M. Stein, K. Hall, J.R. Daugherty, M.R. Griffin Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease an observational cohort study Lancet 359 2002 118 123
10. S.E. Gabriel, L. Jaakkimainen, C. Bombardier Risk for serious gastrointestinal complications related to the use of nonsteroidal anti-inflammatory drugs. A meta-analysis Ann Intern Med 115 1991 787 796
11. W.A. Ray, C.M. Stein, J.R. Daugherty, K. Hall, P.G. Arbogast, M.R. Griffin COX-2 selective non-steroidal anti-inflammatory drugs and risks of serious coronary heart disease Lancet 360 2002 1071 1073
12. M.F. de Queiros Double-blind comparison of etodolac and naproxen in the treatment of rheumatoid arthritis Clin Ther 13 1991 38 46
13. A. Fioravanti, D. Vaccai, F. Megale, C. Dragonetti, A. Iudice, R. Marcolongo Single-blind, randomized, parallel-group study of etodolac and naproxen in patients with osteoarthritis Curr Ther Res 46 1989 648 653
14. A. Maccagno, E. Di Giorgio, A. Romanowicz Effectiveness of etodolac (Lodine) compared with naproxen in patients with acute gout Curr Med Res Opin 12 1991 423 429
15. L. Laine, C. Bombardier, C.J. Hawkey, B. Davis, D. Shapiro, C. Brett, A. Reicin Stratifying the risk of NSAID-related upper gastrointestinal clinical events results of a double-blind outcomes study in patients with rheumatoid arthritis Gastroenterology 123 2002 1006 1012